Physician profile
Carlos D Ramirez
NPI 1932341203
$6,458.19
in general payments reported to CMS, 2019-2025
33 companies · $1,344 in 2025
The $1,344 reported for 2025 was more than what 94% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $405 · 2020: $288 · 2021: $1,443 · 2022: $681 · 2023: $1,131 · 2024: $1,166 · 2025: $1,344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,641.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,457.08 | 2019-2025 | Wavewriter Alpha Prime 16, Infinion 16, General - Pain Management |
| Abbvie INC. | $717.06 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $683.94 | 2019-2025 | Jardiance |
| Amgen INC. | $562.57 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $545.39 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $436.49 | 2019-2025 | Ozempic, Rybelsus |
| Vertos Medical, INC. | $332.18 | 2021-2024 | Mild Device Kit |
| Lilly USA, LLC | $330.32 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Pfizer INC. | $228.01 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $148.76 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.39 | 2021-2024 | Relistor |
| Nestle Healthcare Nutrition INC. | $91.39 | 2021-2022 | |
| Exact Sciences Corporation | $91.22 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $86.81 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $80.77 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $62.84 | 2022-2023 | Quviviq |
| Allergan, INC. | $57.65 | 2019-2020 | |
| Relievant Medsystems, INC. | $52.64 | 2022-2023 | Intracept |
| Philips North America LLC | $45.70 | 2021 | |
| Dexcom, INC. | $45.08 | 2025 | Dexcom G6 Transmitter |
| Merz Pharmaceuticals, LLC | $37.63 | 2023 | Xeomin |
| Bayer Healthcare Pharmaceuticals INC. | $37.46 | 2025 | |
| Nevro Corp. | $31.03 | 2023 | Senza |
| Merit Medical Systems INC | $27.66 | 2021 | |
| Curonix LLC | $24.45 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Scilex Pharmaceuticals INC. | $22.34 | 2022 | |
| Abbott Laboratories | $20.71 | 2019 | |
| Collegium Pharmaceutical, INC. | $18.74 | 2025 | Belbuca |
| Acelrx Pharmaceuticals, INC. | $18.07 | 2022 | |
| Sanofi-Aventis U.S. LLC | $17.54 | 2021 | |
| Sanofi Pasteur INC. | $13.45 | 2019 | |
| Alexion Pharmaceuticals, INC. | $12.61 | 2021 | |
| Grt US Holding, INC. | $12.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.